Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 17:2018:5376476.
doi: 10.1155/2018/5376476. eCollection 2018.

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Chau Yee Ng  1   2   3   4 , Chun-Bing Chen  1   2   3   4 , Ming-Ying Wu  1   2   3 , Jennifer Wu  1   2   3 , Chih-Hsun Yang  1   2   3   4 , Rosaline Chung-Yee Hui  1   2   3   4 , Ya-Ching Chang  1   2   3   4 , Chun-Wei Lu  1   2   3   4
Affiliations
Review

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Chau Yee Ng et al. J Immunol Res. .

Abstract

Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roujeau J. C. Immune mechanisms in drug allergy. Allergology International. 2006;55(1):27–33. doi: 10.2332/allergolint.55.27. - DOI - PubMed
    1. French L. E., Trent J. T., Kerdel F. A. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. International Immunopharmacology. 2006;6(4):543–549. doi: 10.1016/j.intimp.2005.11.012. - DOI - PubMed
    1. Mockenhaupt M., Schopf E. Epidemiology of drug-induced severe skin reactions. Seminars in Cutaneous Medicine and Surgery. 1996;15(4):236–243. doi: 10.1016/S1085-5629(96)80036-8. - DOI - PubMed
    1. Revuz J., Penso D., Roujeau J. C., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of Dermatology. 1987;123(9):1160–1165. doi: 10.1001/archderm.1987.01660330071012. - DOI - PubMed
    1. Roujeau J. C., Guillaume J. C., Fabre J. P., Penso D., Flechet M. L., Girre J. P. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Archives of Dermatology. 1990;126(1):37–42. doi: 10.1001/archderm.1990.01670250043005. - DOI - PubMed

MeSH terms

Substances